Canada | Publication | July 2022
Our 2022 Guide to Canada’s Pharmaceutical Intellectual Property Regime is a convenient all-in-one reference to the important legal and regulatory regimes governing pharmaceuticals in Canada.
The Guide provides a detailed review of the key regimes, including:
We are honoured that the Guide includes a Foreword by our partner, The Right Honourable Brian Mulroney. During his tenure as the 18th Prime Minister of Canada, Mr. Mulroney championed a series of significant legislative reforms to improve protections for pharmaceuticals that continue to operate today. The COVID-19 pandemic has highlighted the importance of fostering investment in research, development and manufacturing by the innovative pharmaceutical industry in Canada. Norton Rose Fulbright’s pharmaceuticals and life sciences team understands the innovative pharmaceutical industry and will continue to work with innovators to defend their rights and maintain the benefits they bring to all Canadians.
We hope this Guide will assist in navigating the complex challenges of this rapidly evolving field.
Publication
On 24 October 2024, the Court of Justice of the European Union (CJEU) confirmed that the European Commission’s (the EC) 2009 decision, which imposed a (then record) €1.06 billion fine on Intel, was flawed as far as it found that loyalty rebates granted by Intel had anti-competitive effects.
Publication
The Dutch tax classification system for non-Dutch entities will undergo significant changes as of 1 January 2025.
Publication
In King Crude Carriers SA & Ors v Ridgebury November LLC & Ors [2024] EWCA Civ 719 the Court of Appeal held that the claimant sellers (the Sellers) were entitled to claim the deposits promised under sale contracts as a debt despite the defendant buyers’ (the Buyers) breach of contract, which had resulted in the non-fulfilment of a condition precedent to the payment of the deposits.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023
